Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 140
Filtrar
1.
Clin Radiol ; 79(6): 404-412, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38565483

RESUMEN

Due to the rising demand in cross-sectional thoracic imaging, anterior mediastinal lesions are being identified with increasing frequency. Following iterative and multidisciplinary discussions, the BTOG Thymic Malignancies Special Interest Group have developed an algorithm to standardise the diagnostic approach for these relatively uncommon but important conditions which span from benign (thymic remnant, thymic hyperplasia and thymic cysts) to suspected localised thymomas to suspected more aggressive malignancy (thymic carcinoma, lymphoma and germ cell tumours). For each condition, we provide a brief description, an overview of the key radiological findings and a description of the proposed algorithm including the rationale behind the recommendations. We also highlight the role of magnetic resonance (MR) imaging for the characterisation of anterior mediastinal masses in specific indications when the necessary local resources and expertise exist. In addition, we hope this provides the rationale for service development in MR of the anterior mediastinum where current resource and expertise requires development. Through this standardised pathway, we hope to drive improvements in patient care by rationalising surveillance schedules, avoiding unnecessary resections of benign entities with their associated morbidity and optimising the diagnostic work-up prior to the appropriate treatment of anterior mediastinal malignancies.


Asunto(s)
Algoritmos , Imagen por Resonancia Magnética , Neoplasias del Mediastino , Neoplasias del Timo , Humanos , Diagnóstico Diferencial , Imagen por Resonancia Magnética/métodos , Neoplasias del Mediastino/diagnóstico por imagen , Mediastino/diagnóstico por imagen , Timoma/diagnóstico por imagen , Neoplasias del Timo/diagnóstico por imagen
4.
QJM ; 116(6): 474-475, 2023 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-36355474

Asunto(s)
Algoritmos , Pacientes , Humanos
9.
QJM ; 114(6): 357-358, 2021 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-33486529

RESUMEN

Disproportionately few clinical trials are undertaken on the African continent, in part due to lingering neocolonial attitudes in the Global North which keep research activity primarily in developing countries, while being skeptical of the abilities of those in the Global South to undertake organized clinical studies. In the era of the COVID-19 pandemic, applicable research and clinical trials should be undertaken in relevant populations in order to extrapolate to a population level. This is all the more important in Africa, which has a rich genetic diversity. We suggest that a lack of organized research ethics committees across the continent and a deficiency of appropriate training are responsible in part for the reluctance of clinical trial organizers in the developed countries of the Global North to engage with medical leadership in Africa. We consider ways of alleviating this problem, including suggesting a pan-continental surveillance of ethics committee agendas and of training, either through the auspices of the African Union or the World Health Organization. In addition, medical leadership in African nations must be encouraged to take ownership of their medical ethics agendas to facilitate decent international clinical trial participation for the good of the continent as a whole.


Asunto(s)
Ensayos Clínicos como Asunto , África , COVID-19 , Humanos , Liderazgo , Pandemias , SARS-CoV-2
10.
QJM ; 114(5): 343, 2021 08 29.
Artículo en Inglés | MEDLINE | ID: mdl-33459782
11.
Science ; 371(6527): 386-390, 2021 01 22.
Artículo en Inglés | MEDLINE | ID: mdl-33479150

RESUMEN

Convergent evolution provides insights into the selective drivers underlying evolutionary change. Snake venoms, with a direct genetic basis and clearly defined functional phenotype, provide a model system for exploring the repeated evolution of adaptations. While snakes use venom primarily for predation, and venom composition often reflects diet specificity, three lineages of cobras have independently evolved the ability to spit venom at adversaries. Using gene, protein, and functional analyses, we show that the three spitting lineages possess venoms characterized by an up-regulation of phospholipase A2 (PLA2) toxins, which potentiate the action of preexisting venom cytotoxins to activate mammalian sensory neurons and cause enhanced pain. These repeated independent changes provide a fascinating example of convergent evolution across multiple phenotypic levels driven by selection for defense.


Asunto(s)
Venenos Elapídicos/enzimología , Elapidae/clasificación , Elapidae/genética , Evolución Molecular , Fosfolipasas A2 Grupo IV/genética , Dolor , Células Receptoras Sensoriales/fisiología , Adaptación Biológica/genética , Animales , Venenos Elapídicos/genética , Filogenia , Células Receptoras Sensoriales/metabolismo
12.
QJM ; 114(9): 680, 2021 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-33283871

Asunto(s)
Jubilación , Humanos
13.
QJM ; 114(5): 291-292, 2021 Aug 29.
Artículo en Inglés | MEDLINE | ID: mdl-33070188

RESUMEN

It has never been clear to me whether being a medically qualified patient has positive or negative associations. In 2019, after a prostatectomy, where I had extended bleeding per urethra, I suffered two myocardial infarctions, underwent three coronary angiograms and eventually coronary stenting. Junior doctors never examined me at any point, while senior ones worried over the risk of stent placement in an actively bleeding patient. I report my views on how this seemed as a largely passive, but still actively thinking patient.


Asunto(s)
Angioplastia Coronaria con Balón , Infarto del Miocardio , Angiografía Coronaria , Hemorragia , Humanos , Masculino , Infarto del Miocardio/terapia , Stents , Resultado del Tratamiento
14.
QJM ; 114(1): 13-15, 2021 Feb 18.
Artículo en Inglés | MEDLINE | ID: mdl-33118021

RESUMEN

If we were told that one day the entire world would take its guidance for managing a health crisis from empirical thought, nobody would have believed it. However, with the December 2019 arrival of COVID-19 in China, the world subsequently went into a frenzied state that resulted in the widespread adoption of untested strategies or potential cures; circumstantial evidence provided without randomized control trials (RCTs) was published rapidly and widely considered the gold standard in medical research and therapeutics. Nigeria and much of the rest of the world blindly adopted treatments like chloroquine or hydroxychloroquine and various prevention strategies, often without monitoring the efficacy of these treatment and social control strategies. COVID-19 provided Nigeria a critical opportunity to create or strengthen its national laboratory system by building up its Level 3 laboratories in all parts of the country with the capability to perform PCR tests and viral isolation. There was also an opportunity to establish hospitals in every region of a sufficient standard to reduce the numbers of Nigerians travelling abroad to seek medical treatment; to invest in building capacity to develop antiviral medications and vaccines in Nigeria, and to ensure better international health policies. Rather, Nigerian leaders, government and health managers decided (like most other nations of the world) to shut down the society using isolationist policies that were not necessarily tailored to local needs. Despite adopting these methods, COVID-19 cases continued to skyrocket in Nigeria. In the future, before adopting such broad sweeping policies, there should be local tailoring to assess their effectiveness in different communities. Given that the country has much experience in controlling Lassa and Marburg Fever outbreaks, Nigeria should lead by developing new strategies, new protocols and new local guidelines, based on validated and reproducible studies to ensure that the public health authorities are not caught unaware by any new outbreaks of emerging or remerging diseases.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , COVID-19 , Gestión del Cambio , Control de Enfermedades Transmisibles , Asistencia Sanitaria Culturalmente Competente , Formulación de Políticas , Salud Pública/normas , COVID-19/epidemiología , COVID-19/prevención & control , COVID-19/terapia , Defensa Civil/normas , Control de Enfermedades Transmisibles/métodos , Control de Enfermedades Transmisibles/organización & administración , Asistencia Sanitaria Culturalmente Competente/legislación & jurisprudencia , Asistencia Sanitaria Culturalmente Competente/métodos , Asistencia Sanitaria Culturalmente Competente/organización & administración , Regulación Gubernamental , Humanos , Nigeria/epidemiología , Distanciamiento Físico , SARS-CoV-2
15.
Acute Med ; 18(3): 197-199, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31536059

RESUMEN

The advent of immunotherapy in oncology has led to the emergence of a new spectrum of adverse effects. A number of these have the potential to contribute to life-threatening outcomes; and therefore require prompt identification and aggressive treatment to optimise management. In this report, we describe a case of pembrolizumab-induced CTCAE (common toxicity criteria for adverse events) grade 4 myositis in a non-small cell lung cancer patient.


Asunto(s)
Adenocarcinoma del Pulmón , Anticuerpos Monoclonales Humanizados , Antineoplásicos Inmunológicos , Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Miositis , Adenocarcinoma del Pulmón/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos Inmunológicos/efectos adversos , Antineoplásicos Inmunológicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Miositis/inducido químicamente
16.
Blood Cancer J ; 7(3): e539, 2017 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-28282033

RESUMEN

Phosphoinositide-3-kinase and protein kinase B (PI3K-AKT) is upregulated in multiple myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus-mediated knockdown and pharmacologic isoform-specific inhibition we investigated the role of the PI3K p110γ (PI3Kγ) subunit in regulating MM proliferation and bone marrow microenvironment-induced MM interactions. We compared this with inhibition of the PI3K p110δ (PI3kδ) subunit and with combined PI3kδ/γ dual inhibition. We found that MM cell adhesion and migration were PI3Kγ-specific functions, with PI3kδ inhibition having no effect in MM adhesion or migration assays. At concentration of the dual PI3Kδ/γ inhibitor duvelisib, which can be achieved in vivo we saw a decrease in AKT phosphorylation at s473 after tumour activation by bone marrow stromal cells (BMSC) and interleukin-6. Moreover, after drug treatment of BMSC/tumour co-culture activation assays only dual PI3kδ/γ inhibition was able to induce MM apoptosis. shRNA lentiviral-mediated targeting of either PI3Kδ or PI3Kγ alone, or both in combination, increased survival of NSG mice xeno-transplanted with MM cells. Moreover, treatment with duvelisib reduced MM tumour burden in vivo. We report that PI3Kδ and PI3Kγ isoforms have distinct functions in MM and that combined PI3kδ/γ isoform inhibition has anti-MM activity. Here we provide a scientific rationale for trials of dual PI3kδ/γ inhibition in patients with MM.


Asunto(s)
Fosfatidilinositol 3-Quinasa Clase I/metabolismo , Fosfatidilinositol 3-Quinasa Clase Ib/metabolismo , Mieloma Múltiple/metabolismo , Mieloma Múltiple/patología , Transducción de Señal , Microambiente Tumoral , Animales , Apoptosis , Adhesión Celular , Línea Celular Tumoral , Movimiento Celular , Proliferación Celular , Supervivencia Celular/genética , Fosfatidilinositol 3-Quinasa Clase I/antagonistas & inhibidores , Modelos Animales de Enfermedad , Xenoinjertos , Humanos , Interleucina-6/metabolismo , Interleucina-6/farmacología , Ratones , Mieloma Múltiple/tratamiento farmacológico , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Isoformas de Proteínas , Subunidades de Proteína , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto
18.
Aliment Pharmacol Ther ; 44(9): 936-945, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27604637

RESUMEN

BACKGROUND: Brain change can occur in primary biliary cholangitis (PBC), potentially as a result of cholestatic and/or inflammatory processes. This change is linked to systemic symptoms of fatigue and cognitive impairment. AIM: To identify whether brain change occurs early in PBC. If the change develops early and is progressive, it may explain the difficulty in treating these symptoms. METHODS: Early disease brain change was explored in 13 patients with newly diagnosed biopsy-proven precirrhotic PBC using magnetisation transfer, diffusion-weighted imaging and 1 H magnetic resonance spectroscopy. Results were compared to 17 healthy volunteers. RESULTS: Cerebral magnetisation transfer ratios were reduced in early PBC, compared to healthy volunteers, in the thalamus, putamen and head of caudate with no greater reduction in patients with greater symptom severity. Mean apparent diffusion coefficients were increased in the thalamus only. No 1 H magnetic resonance spectroscopy abnormalities were seen. Serum manganese levels were elevated in all PBC patients, but no relationship was seen with imaging or symptom parameters. There were no correlations between neuroimaging data, laboratory data, symptom severity scores or age. CONCLUSIONS: This is the first study to be performed in this precirrhotic patient population, and we have highlighted that neuroimaging changes are present at a much earlier stage than previously demonstrated. The neuroimaging abnormalities suggest that the brain changes seen in PBC occur early in the pathological process, even before significant liver damage has occurred. If such changes are linked to symptom pathogenesis, this could have important implications for the timing of second-line-therapy use.


Asunto(s)
Encéfalo/anomalías , Encéfalo/diagnóstico por imagen , Colangitis/diagnóstico por imagen , Imagen de Difusión por Resonancia Magnética/métodos , Adulto , Anciano , Diagnóstico Precoz , Femenino , Humanos , Cirrosis Hepática Biliar/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Espectroscopía de Resonancia Magnética/métodos , Masculino , Persona de Mediana Edad
19.
Aliment Pharmacol Ther ; 43(3): 375-84, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26623967

RESUMEN

BACKGROUND: In sub-Saharan Africa, it is unknown whether hepatitis E virus (HEV) infection is a common precipitating event of acute-on-chronic liver failure (ACLF). AIMS: To estimate the prevalence of HEV infection in general population and assess whether HEV is a common trigger of ACLF in cirrhotic patients in The Gambia, West Africa. METHODS: We first conducted an HEV sero-survey in healthy volunteers. We then tested cirrhotic patients with ACLF (cases) and compensated cirrhosis (controls) for anti-HEV IgG as a marker of exposure to HEV, and anti-HEV IgA and HEV RNA as a marker of recent infection. We also described the characteristics and survival of the ACLF cases and controls. RESULTS: In the healthy volunteers (n = 204), 13.7% (95% CI: 9.6-19.2) were positive for anti-HEV IgG, and none had positive HEV viraemia. After adjusting for age and sex, the following were associated with positive anti-HEV IgG: being a Christian, a farmer, drinking water from wells, handling pigs and eating pork. In 40 cases (median age: 45 years, 72.5% male) and 71 controls (39 years, 74.6% male), ≥70% were infected with hepatitis B virus. Although hepatitis B flare and sepsis were important precipitating events of ACLF, none had marker of acute HEV. ACLF cases had high (70.0%) 28-day mortality. CONCLUSIONS: Hepatitis E virus infection is endemic in The Gambia, where both faecal-oral route (contaminated water) and zoonotic transmission (pigs/pork meat) may be important. However, acute HEV was not a common cause of acute-on-chronic liver failure in The Gambia.


Asunto(s)
Insuficiencia Hepática Crónica Agudizada/epidemiología , Hepatitis E/epidemiología , Cirrosis Hepática/epidemiología , Adulto , Agricultura , Estudios de Casos y Controles , Femenino , Gambia/epidemiología , Anticuerpos Antihepatitis/sangre , Virus de la Hepatitis E/genética , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , ARN Viral , Factores Socioeconómicos , Abastecimiento de Agua
20.
J Viral Hepat ; 23(1): 39-46, 2016 01.
Artículo en Inglés | MEDLINE | ID: mdl-26306786

RESUMEN

Hepatitis C virus (HCV) causes not only liver damage in certain patients but can also lead to neuropsychiatric symptoms. Previous studies have shown that the type 4 allele of the gene for apolipoprotein E (APOE) is strongly protective against HCV-induced damage in liver. In this study, we have investigated the possibility that APOE genotype is involved in the action of HCV in brain. One hundred HCV-infected patients with mild liver disease underwent a neurological examination and a comprehensive psychometric testing of attention and memory function. In addition, patients completed questionnaires for the assessment of fatigue, health-related quality of life and mood disturbances. Apolipoprotein E gene genotyping was carried out on saliva using buccal swabs. The APOE-ε4 allele frequency was significantly lower in patients with an impairment of working memory, compared to those with a normal working memory test result (P = 0.003). A lower APOE-ε4 allele frequency was also observed in patients with definitely altered attention ability (P = 0.008), but here, the P-value missed the level of significance after application of the Bonferroni correction. Our data suggest that the APOE-ε4 allele is protective against attention deficit and especially against poor working memory in HCV-infected subjects with mild liver disease. Considering the role of apolipoprotein E in the life cycle of the virus, the findings shed interesting new light upon possible pathomechanisms behind the development of neuropsychiatric symptoms in hepatitis C infection.


Asunto(s)
Apolipoproteína E4/deficiencia , Disfunción Cognitiva/psicología , Encefalopatía Hepática/psicología , Hepatitis C Crónica/patología , Memoria a Corto Plazo/fisiología , Trastornos del Humor/psicología , Enfermedades Neurodegenerativas/psicología , Adulto , Anciano , Alelos , Apolipoproteína E4/genética , Cognición , Disfunción Cognitiva/virología , Femenino , Frecuencia de los Genes/genética , Hepacivirus/genética , Encefalopatía Hepática/virología , Hepatitis C Crónica/virología , Humanos , Hígado/patología , Hígado/virología , Masculino , Persona de Mediana Edad , Trastornos del Humor/virología , Enfermedades Neurodegenerativas/virología , Pruebas Neuropsicológicas , Calidad de Vida/psicología , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...